Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Well, no danger of immediate offering in the very near future:
Exercise of Existing Warrants Resulting in $4 Million Proceeds to the Company
RedHill Biopharma (Nasdaq: RDHL) today announced the exercise, between November 27, 2023 and November 29, 2023, of certain existing warrants (the “Existing Warrants”) to purchase 8,603,846 American Depository Shares (“ADSs”), originally issued pursuant to the Company financing closed on October 3, 2023, for a total of approximately $4 million gross proceeds to the Company. Following the exercise of the warrants, a significant prior warrants overhang was removed, and the Company’s outstanding share capital consists of 19,674,633 ADSs.
Heaven forbid they would make more cuts to the company to save money. Why in the world do they still need 100 employees?
An offereing would be an absolute dagger and kill all the momenteum we now have. That being said it is such the redhill way and would not shock me in the least. We would be trading below a buck again in no time.
An offereing would be an absolute dagger and kill all the momenteum we now have. That being said it is such the redhill way and would not shock me in the least. We would be trading below a buck again in no time.
RedHill Biopharma Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency
September 22 2023 - 04:15PM
The bid price of the Company's ADSs closes at $1.00 per share or more for a minimum of ten consecutive business days hence is now in compliance with Nasdaq rules.
I just hope they have some cash the last thing we need is another dilution it will call all the gains we have made the last week.
Earnings announcement* for RDHL: Dec 5, 2023
Anyone know the time?
Still concerned about the 3rd quarter financials though I really doubt they had much cash left and will look to dilute us again. Hope I am wrong.
Lol miracles do happen.
I am honestly stunned this company is back from the dead. I was few weeks away from unloading it all for a tax loss. I thought for sure they were cooked.
Herewith an example of another Israeli company earning a stockpiling
contract, although for a different indication:
MediWound Announces an Additional $10 Million Award from BARDA
May 9, 2023
Funding to support emergency stockpiling replenishment, pediatric indication submission, and expanded access treatment protocol extension
YAVNE, Israel, May 09, 2023 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company focused on next-generation enzymatic therapeutics for tissue repair, today announced that the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS), has awarded an additional $10 million to MediWound. The supplemental funding will support a $3 million replenishment of expired product previously procured for emergency preparedness, the pediatric indication sBLA submission to the U.S. Food and Drug Administration (FDA), and enrollment of an additional 50 patients in the ongoing expanded access treatment protocol (NEXT).
MediWound was awarded its first BARDA contract for treatment of thermal burn injuries in 2015. This contract, now valued at up to $175 million, supported advanced development and manufacturing, as well as the procurement of NexoBrid as a medical countermeasure as part of U.S. emergency preparedness for a mass casualty. Under that contract, BARDA provided technical assistance and a total of up to $98 million for NexoBrid development activities required for U.S. marketing approval from the FDA. These activities include the NexoBrid Phase 3 study (DETECT) and subsequent BLA resubmission requirements, the pediatric Phase 3 study (CIDS), and the NexoBrid expanded access treatment protocol (NEXT). In January 2020, BARDA committed an additional $16.5 million to procure NexoBrid as part of the HHS mission to build national preparedness for public health medical emergencies. The contract further includes a $10 million option to fund development of other potential NexoBrid indications, and an option to procure additional NexoBrid valued at up to $47 million.
https://ir.mediwound.com/news-releases/news-release-details/mediwound-announces-additional-10-million-award-barda-0
Mind you, i am not promoting MDWD, rather proving my point that RDHL stands a good chance of winning a similar sized contract.
With RDHL m/c the impact could be enormous. (The question is if and when)
LOL, i wish i knew, but i'll take a bet:
6 months from now, latest.
Fingers crossed.
When do you expect that?
The much better news i expect is:
RedHill Announces New, Non-Dilutive External Funding of Entire RHB-107 COVID-19 300-Patient Phase 2 Study
https://finance.yahoo.com/news/redhill-announces-non-dilutive-external-120000300.html
The new non-dilutive external funding, additional to the previously announced U.S. Government non-dilutive funding, now covers the entirety of the RHB-107 (upamostat)[1] arm of the ACESO PROTECT adaptive platform trial for early COVID-19 outpatient treatment
This additional funding amounts to approximately $4.8M directed towards evaluation of RHB-107 in the PROTECT study
In addition to the platform's Master Protocol, the 300-patient Phase 2 RHB-107 arm has received FDA clearance to start, with the first patient expected to be enrolled in the coming weeks. The study is being conducted in the U.S., Thailand, Ivory Coast, South Africa and Uganda, and is estimated to be completed by end of 2024
RHB-107 successfully met the primary endpoint of safety and tolerability and delivered promising efficacy results, including marked reduction in hospitalization due to COVID-19 in a U.S. Phase 2 study[2]
If approved, RHB-107, a novel, oral, once-daily, host-directed potential broad-acting antiviral expected to act independently of viral spike protein mutations[3], would target the multi-billion-dollar early COVID-19 treatment market
RALEIGH, N.C. and TEL-AVIV, Israel, Dec. 4, 2023 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced new non-dilutive external funding, additional to the previously announced U.S. Government funding, which now covers the entirety of the RHB-107 (upamostat) arm of the ACESO PROTECT adaptive platform trial for early COVID-19 outpatient treatment. This additional funding amounts to approximately $4.8M directed towards evaluation of RHB-107 in the PROTECT study.
The 300-patient Phase 2 RHB-107 arm of the PROTECT study has received FDA clearance to start, with the first patient expected to be enrolled in the coming weeks. The study is being conducted in the U.S., Thailand, Ivory Coast, South Africa and Uganda, and is estimated to be completed by end of 2024.
"The new non-dilutive external funding, covering the entirety of the RHB-107 arm of the ACESO PROTECT study, is, we believe, indicative of the ongoing and pressing medical need for new oral, small molecule, treatment options for early COVID-19 and demonstrates the need to test the ability of new potential therapeutics, such as RHB-107, to provide such an option. We believe that the PROTECT study could add significant validating data to the previous marked reduction in hospitalizations due to COVID-19 seen in the RHB-107 arm of our earlier U.S. Phase 2 study," said Gilead Raday, RedHill's Chief Operating Officer and Head of R&D. "RHB-107 is a novel, once daily, orally-administered, potentially broad-acting, host-directed small molecule drug that is expected to act independently of viral spike protein mutations. If approved, RHB-107 could provide a much-needed additional option to Paxlovid in the billion-dollar early COVID-19 treatment space."
Data from RHB-107's previous U.S. Phase 2 study showed a 100% reduction in hospitalization due to COVID-19, with zero patients (0/41) on the RHB-107 arms versus 15% (3/20) hospitalized for COVID-19 on the placebo-controlled arm (nominal p-value=0.0317). The study also showed an approximately 88% reduction in reported new severe COVID-19 symptoms after treatment initiation, with 2.4% of the RHB-107 treated group (1/41) versus 20% (4/20) of patients in the placebo-controlled arm (nominal p-value=0.036) reporting new severe COVID-19 symptoms. Further post-hoc analysis showed faster recovery periods from severe COVID-19 symptoms with a median of 3 days to recovery with upamostat compared to 8 days with the placebo.
The ACESO PROTECT study is an adaptive, randomized, double blind, multi-site Phase 2 platform trial, being conducted by researchers from ACESO and partner organizations, and administered by the Henry M. Jackson Foundation for the Advancement of Military Medicine (HJF). The study will compare investigational products (IPs) to control, in standard-risk, non-hospitalized adult SARS-CoV-2 infected participants with at least two moderate-severe symptoms at baseline. RHB-107 is the initial drug being evaluated in the early treatment arm of the study. The primary efficacy assessment in the early treatment indication will be time to sustained alleviation or resolution of COVID-19 symptoms. Participants will be followed for a period of up to 12 weeks.
Selection of IPs for inclusion in the ACESO PROTECT study is based on review of the preclinical and early clinical data, evaluating safety, tolerability, and efficacy. Selection is also based on route of administration and product availability. RHB-107 is the first drug to be studied in the ACESO PROTECT study.
RHB-107's development for COVID-19 runs parallel to the development of opaganib, RedHill's other novel oral drug, for Acute Radiation Syndrome, being done in collaboration with, and funded by, the U.S. government's National Institutes of Health Radiation and Nuclear Countermeasures Program.
About RHB-107 (upamostat)
RHB-107 is a proprietary, first-in-class, once-daily orally administered investigational drug, that targets human serine proteases involved in preparing the spike protein for viral entry into target cells. Because it is host-cell targeted, RHB-107 is expected to also be effective against emerging viral variants with mutations in the spike protein. RHB-107 is well tolerated; in the initial COVID-19 study, among 41 patients only one reported a drug-related adverse reaction (a mild, self-limited, rash).
In addition, RHB-107 inhibits several proteases targeting cancer and inflammatory gastrointestinal disease. RHB-107 has undergone several Phase 1 studies and two Phase 2 studies, demonstrating a clinically safe profile in approximately 200 patients to date2.
RedHill acquired the exclusive worldwide rights to RHB-107, excluding China, Hong Kong, Taiwan and Macao, from Germany's Heidelberg Pharmaceuticals (FSE: HPHA) (formerly WILEX AG) for all indications.
About HJF
The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. (HJF), now celebrating its 40th anniversary, is a global nonprofit organization with the mission to advance military medicine. HJF's scientific, administrative and program operations services empower investigators, clinicians, and medical researchers around the world to make discoveries in all areas of medicine. HJF serves as a trusted and responsive link between the military medical community, federal and private partners, and the millions of warfighters, veterans, and civilians who benefit from military medicine. For more information, visit www.hjf.org.
About ACESO
The Austere environments Consortium for Enhanced Sepsis Outcomes (ACESO) aims to improve survival for patients with sepsis in resource-limited settings through development of host-based technology solutions and evidence-based clinical management strategies. Founded in 2010, ACESO brings together a consortium comprised of academic, non-profit, governmental, and industry partners that is administered by HJF. ACESO has established a global clinical research network to develop and deliver cutting-edge tools and strategies to save lives in austere settings.
For more information, visit www.aceso-sepsis.org.
About RedHill Biopharma
RedHill Biopharma Ltd. (Nasdaq: RDHL) is a specialty biopharmaceutical company primarily focused on gastrointestinal and infectious diseases. RedHill promotes the gastrointestinal drugs Talicia®, for the treatment of Helicobacter pylori (H. pylori) infection in adults[4], and Aemcolo®, for the treatment of travelers' diarrhea in adults[5]. RedHill's key clinical late-stage development programs include: (i) opaganib (ABC294640), a first-in-class oral broad-acting, host-directed SPHK2 selective inhibitor with potential for pandemic preparedness, targeting multiple indications with a U.S. government collaboration for development for Acute Radiation Syndrome (ARS), a Phase 2/3 program for hospitalized COVID-19, and a Phase 2 program in oncology; (ii) RHB-107 (upamostat), an oral broad-acting, host-directed, serine protease inhibitor with potential for pandemic preparedness is in late-stage development as a treatment for non-hospitalized symptomatic COVID-19, and is also targeting multiple other cancer and inflammatory gastrointestinal diseases; (iii) RHB-102, with potential UK submission for chemotherapy and radiotherapy induced nausea and vomiting, positive results from a Phase 3 study for acute gastroenteritis and gastritis and positive results from a Phase 2 study for IBS-D; (iv) RHB-104, with positive results from a first Phase 3 study for Crohn's disease; and (v) RHB-204, a Phase 3-stage program for pulmonary nontuberculous mycobacteria (NTM) disease.
More information about the Company is available at: www.redhillbio.com / twitter.com/RedHillBio.
Bottom is in. Ready for short squeeze…
If u don’t like go away and make money somewhere else
The basher below sold at .67 and has been bashing since then
16$ bogus price target pumpers. Its @$1.88 far from $16
Time to load up. Me likey discounts…..
I'm confused. Back in 2018 the company released similar news granted GAIN/QIDP. Why this time is different?
https://markets.businessinsider.com/news/stocks/redhill-biopharma-announces-enrollment-of-300th-patient-in-confirmatory-phase-iii-study-with-talicia-for-h-pylori-infection-1023374634
I am telling you million of dollars waiting for this company back to 16 dollars soon
This is very interesting IMHO.
“Talicia is the only FDA-approved rifabutin-based therapy for the eradication of H. pylori. Its components and formulation are optimized to provide patients with the necessary medications for successful H. pylori eradication, an innovation rewarded by this market exclusivity and other IP, providing protection to 2034.” ...
... Still, the fundamental case for RDHL stock centers on the potential total addressable market. According to the Mayo Clinic, H. pylori is a form of bacterial infection in the stomach. Typically, this condition occurs in childhood. Moreover, H. pylori infection may be present in more than half the people in the world.
Under this context, it’s not surprising that several hedge funds appear willing to gamble on RDHL stock. Per data compiled by Whale Wisdom, the top five hedge funds based on increased change in shares are as follows:
• Armistice Capital, LLC acquired an additional 722,894 shares.
• Sabby Management, LLC acquired an additional 635,006 shares.
• Empery Asset Management, LP acquired an additional 147,653 shares.
• Gagnon Securities LLC acquired an additional 47,695 shares.
• Citadel Advisors LLC acquired an additional 40,050 shares.
$RDHL
Nothing to worry about because it will go back to 16
Money machine
Buy more as it drops more money in the bank
Why Is Redhill Biopharma (RDHL) Stock Down 27% Today?
Story by William White - now
Redhill Biopharma (NASDAQ:RDHL) stock is sliding lower on Thursday but only after the company’s shares come off of a recent rally.
Shares of RDHL stock saw major gains earlier in the week. That came after the Food and Drug Administration (FDA) granted it five-year market exclusivity for Talicia. This is the company’s helicobacter pylori treatment.
That announcement has seen shares of RDHL stock make strong climbs every day this week since Monday. However, the stock seems to finally be running out of steam with today’s dip.
RDHL Stock Movement on Thursday
The early morning trading of RDHL stock has more than 3.5 million shares of the stock changing hands as of this writing. For the record, the company’s daily average trading volume is still above that at roughly 8.9 million shares.
While RDHL stock is slipping today, it’s not something investors will likely need to worry over. Instead, it looks like the stock is simply settling to a more reasonable price after this week’s gains.
RDHL stock is down 27.1% as of Thursday morning. For the record, the stock is down 59.3% since the start of the year.
Investors who want to know more about the latest stock market news today will want to keep reading!
https://www.msn.com/en-us/money/markets/why-is-redhill-biopharma-rdhl-stock-down-27-today/ar-AA1kN1tP
===============
5 Investors Betting Big on RedHill Biopharma (RDHL) Stock
Market whales may anticipate even higher returns
2d ago · By Josh Enomoto, InvestorPlace Contributor
• Shares of RedHill Biopharma (RDHL) skyrocketed to start the final week of November.
• The FDA granted a five-year market exclusivity for RedHill’s drug Talicia.
• RDHL stock also enjoys support from big-time investors.
Amid a slow start to the new week, specialty drug developer RedHill Biopharma (NASDAQ:RDHL) dramatically enlivened the mood, skyrocketing over 180% during the early afternoon session. Catapulting sentiment was regulatory approval for Talicia, a therapeutic designed to target helicobacter pylori (H. pylori). Even more enticing, several hedge funds own RDHL stock, indicating possible sustained upside potential.
According to the accompanying press release, the U.S. Food and Drug Administration (FDA) granted a five-year market exclusivity for Talicia under the Generating Antibiotic Incentives Now (GAIN) Act Qualified Infectious Disease Product (QIDP) designation. Further, the document states that a broad intellectual property suite protects the therapeutic to 2034. RedHill Senior Vice President of Regulatory Affairs Patricia Anderson emphasized the importance of the announcement:
“Talicia is the only FDA-approved rifabutin-based therapy for the eradication of H. pylori. Its components and formulation are optimized to provide patients with the necessary medications for successful H. pylori eradication, an innovation rewarded by this market exclusivity and other IP, providing protection to 2034.”
Adding to sentiment for RDHL stock, the aforementioned grant is on top of the three years’ exclusivity, which came with the approval of Talicia, per a Seeking Alpha report.
A Relevance Shift May Shine a New Light on Risky RDHL Stock
While RDHL stock represents a massive winner on Monday, it can’t be ignored that the underlying enterprise is extraordinarily risky. Since the beginning of the year, shares have lost around 86% of their equity value. That alone should be enough to warrant extreme caution.
Still, the fundamental case for RDHL stock centers on the potential total addressable market. According to the Mayo Clinic, H. pylori is a form of bacterial infection in the stomach. Typically, this condition occurs in childhood. Moreover, H. pylori infection may be present in more than half the people in the world.
Under this context, it’s not surprising that several hedge funds appear willing to gamble on RDHL stock. Per data compiled by Whale Wisdom, the top five hedge funds based on increased change in shares are as follows:
• Armistice Capital, LLC acquired an additional 722,894 shares.
• Sabby Management, LLC acquired an additional 635,006 shares.
• Empery Asset Management, LP acquired an additional 147,653 shares.
• Gagnon Securities LLC acquired an additional 47,695 shares.
• Citadel Advisors LLC acquired an additional 40,050 shares.
In addition to the massive addressable market, a research paper published by the National Library of Medicine sheds light on Talicia’s possible social equity implications. “The prevalence of H. pylori infection varies widely by geographic area, age, race, ethnicity, and SES [socioeconomic status]. Rates appear to be higher in developing than in developed countries…” the paper stated in part.
Why It Matters
Presently, no analyst covers RDHL stock, per TipRanks. That may be due to the severe financial risks that RedHill faces. According to investment data aggregator Gurufocus, it identified nine red flags. That said, the aforementioned hedge funds appear to have bought RDHL at higher prices than where it currently stands. Therefore, the implication is that these alpha players will wait it out.
https://investorplace.com/2023/11/5-investors-betting-big-on-redhill-biopharma-rdhl-stock/
$RDHL
Well so much for that idea.
Excellent. I'm back in now but watching it closely.
16$ lol, bogus price target pumpers are the funniest …
RDHL featured again in this video
I got out at 3.00, houdini!
It will be fine i am not worried millions of dollars waiting for them
Aand back down again. It went up 4.10 premarket and had been trending down until that huge buy.
Wow, it sure did. Tripped the circuit breaker again too.
It will recover
2.7800+0.5000 (+21.9298%)
As of 10:13AM EST. Market open.
Pullback, lol
Going to 16 dollars you heard here first
The cd guy sold at 0.68 because this is when started bashing
Just read his previous messages
Can you imagine the impact on sp when further news is announced in regards this news item, eg an emergency stockpiling contract?:
RedHill Announces Additional U.S. Government Funding for Opaganib Nuclear Countermeasure Development
July 21 2023 - 07:00AM
https://www.prnewswire.com/news-releases/redhill-announces-additional-us-government-funding-for-opaganib-nuclear-countermeasure-development-301882889.html
Opaganib awarded a further $1.7 million in U.S. Government funding for development as a medical countermeasure for gastrointestinal acute radiation syndrome (ARS)
I am quite optimistic about this would be item:
RedHill and U.S. Army Announce Opaganib's Ebola Virus Disease Survival Benefit in U.S. Army-Funded In-Vivo Study
https://finance.yahoo.com/news/redhill-u-army-announce-opaganibs-110000709.html
- Novel, oral opaganib, delivered a statistically significant increase in survival time (at 150 mg/kg BID) in a U.S. Army-funded in vivo Ebola virus study
- Opaganib is believed to be the first host-directed molecule to show activity in Ebola virus disease, having previously shown in vitro benefit in several strains of Ebola virus disease models
- Twice daily administered opaganib has previously demonstrated antiviral benefit in late-stage clinical studies of patients hospitalized with moderate to severe COVID-19; opaganib was also selected by the NIH Radiation and Nuclear Countermeasures Program (RNCP) for Acute Radiation Syndrome development
Hopefully RDHL can partner some BP to further
distribute the drug in additional regions.
Followers
|
96
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
3967
|
Created
|
02/25/13
|
Type
|
Free
|
Moderators midastouch017 |
NCI
BARDA
U.S. Department of Defense
FDA Office of Orphan Products Development
Top-line data from the 270-patient global Phase 2/3 COVID-19 study expected Q1/2021
Top-line data from the 40-patient U.S. Phase 2 study of opaganib in severe COVID-19 expected in the coming days; this non-powered study was designed to evaluate safety and potential identification of preliminary efficacy signals in support of the global Phase 2/3 study of opaganib
(Posted 12/22/2020)
21 Ha'arba'a Street
Tel Aviv 6473921
Israel
972 3 541 3131
http://www.redhillbio.com
[1] https://www.redhillbio.com/RedHill/Templates/showpage.asp?DBID=1&LNGID=1&TMID=178&FID=1358&PID=0&IID=1899
[2] https://www.redhillbio.com/RedHill/Templates/showpage.asp?DBID=1&LNGID=1&TMID=178&FID=2432&PID=0&IID=17299
PER IHUB MGMT |
02-07-2021
DISCLAIMER: ONLY FOR MICK
https://investorshub.advfn.com/boards/profilea.aspx?user=1012
*The Board Monitor and herewithin , are not licensed brokers and assume NO responsibility for actions,
investments,decisions, or messages posted on this forum.
CONTENT ON THIS FORUM SHOULD NOT BE CONSIDERED ADVISORY NOR SOLICITATION
AUTHORS MAY HAVE BUYS OR SELLS WITH THE COMPANIES MENTIONED IN TRADING POSTERS SHOULD DUE DILIGENT BUYING OR SELLING.
ALL POSTING SHOULD BE CONSIDERED FOR INFORMATION ONLY. WE DO NOT RECOMMEND ANYONE BUY OR SELL ANY SECURITIES POSTED HEREWITHIN.
ANY trade entered into risks the possibility of losing the funds invested.
• There are no guarantees when buying or selling any security.Any
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |